In oncology, timing is everything. The sooner we know which therapies will work — and which won’t — the faster we can deliver better outcomes for patients and avoid costly trial failures. Yet traditional models often fall short, offering incomplete insights that don’t always translate to human biology.
At ProxyBio, we see organoids as a turning point. Derived directly from patient tissue, organoids serve as living biopsies — faithfully recreating the complexity of tumors outside the body. With them, we can test therapies dynamically, observe resistance as it emerges, and generate predictive biomarkers to guide treatment.
But organoids are only part of the story. To truly unlock their potential, we built CLARITY, our AI platform that integrates single-cell organoid profiling with advanced analytics. CLARITY captures cancer’s hidden subpopulations — the cells that drive relapse and resistance — and transforms that complexity into clear, actionable insight.
The result is a more powerful way to evaluate therapies before they reach patients. In partnership with pharmaceutical companies, our technology has already helped identify drug candidates with strong anti-tumor effects while avoiding toxic side effects missed by traditional models. For patients, this means therapies with a higher chance of success and a lower risk of harm.
Innovation alone, however, is not enough. True progress in healthcare comes from collaboration. That’s why we approach our work with humility — knowing that the answers won’t come from one company alone, but from a network of partners across science, medicine, and technology.
By uniting organoid science with AI and working hand in hand with the broader community, we believe we can illuminate a path forward: one where precision medicine is not an aspiration but a standard of care.
